Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 13M | 449.4% |
| Gross Profit | 2.7M | 133.3% |
| Cost of Revenue | 9.9M | 6.1% |
| Operating expense | 25M | 11.1% |
| Net Income | -12M | 52.6% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 170M | 5.4% |
| Total Liabilities | 168M | 1.3% |
| Total Equity | 1M | 87.6% |
| Shares Outstanding | 123M | 0.2% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -8.6M | 60.8% |
| Cash from investing | 28M | 416.3% |
| Cash from financing | -23,000 | 115% |
EPS
Financial Highlights for Mersana Therapeutics in Q3 '24
Mersana Therapeutics reported a revenue of 13M, which is a 449.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.7M, marking a 133.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 9.9M, a -6.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 25M, showing a -11.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -12M, showing a 52.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Mersana Therapeutics with growth in revenue, gross profit, and net income.
